PubMed Journals Articles About "Apomorphine Injection Parkinson Disease" - Page: 4 RSS

04:21 EST 18th January 2019 | BioPortfolio

Apomorphine Injection Parkinson Disease PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Apomorphine Injection Parkinson Disease articles that have been published worldwide.

More Information about "Apomorphine Injection Parkinson Disease" on BioPortfolio

We have published hundreds of Apomorphine Injection Parkinson Disease news stories on BioPortfolio along with dozens of Apomorphine Injection Parkinson Disease Clinical Trials and PubMed Articles about Apomorphine Injection Parkinson Disease for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Apomorphine Injection Parkinson Disease Companies in our database. You can also find out about relevant Apomorphine Injection Parkinson Disease Drugs and Medications on this site too.

Showing "apomorphine injection Parkinson Disease" PubMed Articles 76–100 of 23,000+

Stroke in Parkinson's Disease.

The association between Parkinson's disease (PD) and stroke remains completely understood.

Death after diagnosis of non-communicable disease comorbid conditions, stratified by injection drug use.

Describe all-cause mortality associated with history of injection drug use (IDU) after a validated diagnosis of four non-communicable disease (NCD) diagnoses: 1) end-stage liver disease (ESLD); 2) end-stage renal disease (ESRD); 3) cancer; or 4) myocardial infarction (MI) or stroke.

Parkinson's Disease: Mitochondria Parked at the ER Hit the Snooze Button.

Parkinson's disease patients report sleep disturbances well ahead of motor symptoms. In this issue of Neuron, Valadas et al. (2018) report that the disease genes pink1 and parkin exert novel, cell-type-specific effects to modulate ER-mitochondria contacts, neuropeptidergic transmission, and sleep patterns.

Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study.

Safinamide (Xadago) is a newly approved selective MAO-B inhibitor for the treatment of Parkinson's Disease (PD). The X-TRA study investigated the efficacy and tolerability of the substance under clinical practice conditions.

Early-onset Parkinson disease caused by a mutation in CHCHD2 and mitochondrial dysfunction.

Our goal was to identify the gene(s) associated with an early-onset form of Parkinson disease (PD) and the molecular defects associated with this mutation.

Is treatment with stem cells effective in Parkinson's disease?

There are many patients with Parkinson's disease who have a limited response to conventional pharmacological treatment. The use of stem cells has been postulated as an alternative, although its effectiveness remains a matter of controversy.

Acute dementia after deep brain stimulation in Parkinson's disease.

It is not clear whether cognitive adverse events can occur after subthalamic nuclei deep brain stimulation in Parkinson's disease, and the putative mechanisms are poorly understood.

A randomized, controlled pilot study of the effects of vitamin D supplementation on balance in Parkinson's disease: Does age matter?

To explore if short term, high dose vitamin D supplementation is safe and improves balance in persons with Parkinson's disease (PD).

Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4).

α-synuclein is a lead Parkinson's disease (PD) biomarker. There are conflicting reports regarding accuracy of α-synuclein in different tissues and biofluids as a PD biomarker, and the within-subject anatomical distribution of α-synuclein is not well described. The Systemic Synuclein Sampling Study (S4) aims to address these gaps in knowledge. The S4 is a multicenter, cross-sectional, observational study evaluating α-synuclein in multiple tissues and biofluids in PD and healthy controls (HC).

Parkinson's disease versus ageing: different postural responses to soleus muscle vibration.

Impairments of postural stability occur with increasing age and in neurodegenerative diseases like the Parkinson's disease (PD). While changes in balance have been described in many studies under steady-state conditions, less is known about the dynamic changes in balance following sudden transition to different sensory inputs.

Vinpocetine regulates levels of circulating TLRs in Parkinson's disease patients.

The pathogenesis of Parkinson's disease (PD) is complex; it includes mitochondrial dysfunction, oxidative stress, and neuroinflammation. Notably, Toll-like receptors (TLRs) may activate inflammatory or anti-inflammatory responses in Parkinson's disease. Vinpocetine has been tested as an anti-inflammatory in both animal and in vitro research. Thus, it is important to test whether the anti-inflammatory properties of vinpocetine may have a protective effect in PD patients.

Anxiety in Parkinson's disease is associated with reduced structural covariance of the striatum.

Anxiety is highly prevalent in Parkinson's disease (PD) and has great negative impact on quality of life. Functional and structural neuroimaging studies have contributed to our understanding of the symptomatology of PD but still little is known about the pathophysiology of PD-related anxiety.

Temperament Traits And Executive Functions In Parkinson's Disease.

aim of the study was to evaluate the possible relationship between Temperament traits and executive dysfunction in patients with Parkinson's disease (PD).

Single Inflammatory Trigger Leads to Neuroinflammation in LRRK2 Rodent Model without Degeneration of Dopaminergic Neurons.

Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common genetic risk factor for Parkinson's disease (PD). While the corresponding pathogenic mechanisms remain largely unknown, LRRK2 has been implicated in the immune system.

Charting the onset of Parkinson-like motor and non-motor symptoms in nonhuman primate model of Parkinson's disease.

Parkinson's disease is a progressive neurodegenerative disease increasingly affecting our aging population. Remarkable advances have been made in developing novel therapies to control symptoms, halt or cure the disease, ranging from physiotherapy and small molecules to cell and gene therapy. This progress was enabled by the existence of reliable animal models. The nonhuman primate model of Parkinson's disease emulates the cardinal symptoms of the disease, including tremor, rigidity, bradykinesia, postural i...

Prevalence and Associated Factors of Sarcopenia and Frailty in Parkinson's Disease: A Cross-Sectional Study.

Sarcopenia and frailty are found in up to one-third of the general elderly population. Both are associated with major adverse health outcomes such as nursing home placement, disability, decreased quality of life, and death. Data on the frequency of both syndromes in Parkinson's disease (PD), however, are very limited.

Medicine Administration in People with Parkinson's Disease in New Zealand: An Interprofessional, Stakeholder-Driven Online Survey.

Medicine administration errors are twice as frequent in people with dysphagia than in those without. Medicine administration is particularly critical for people with Parkinson's disease where late, or missed doses reduce medicine effectiveness and impact on the quality of life. The aim of this study was to explore the current medicine administration practices of people with Parkinson's disease in New Zealand. A self-administered online survey was developed by an interprofessional group including people with...

Adenosine role in brain functions: Pathophysiological influence on Parkinson's disease and other brain disorders.

Although adenosine plays a key role in multiple motor, affective, and cognitive processes, it has received less attention in the neuroscience field compared to other neurotransmitters (e.g., dopamine). In this review, we highlight the role of adenosine in behavior as well as its interaction with other neurotransmitters, such as dopamine. We also discuss brain disorders impacted by alterations to adenosine, and how targeting adenosine can ameliorate Parkinson's disease motor symptoms. We also discuss the rol...

Movement disorder society criteria for clinically established early Parkinson's disease.

In 2015, the International Parkinson and Movement Disorder Society published clinical diagnostic criteria for Parkinson's disease (PD). Although recent validation studies suggest high accuracy, one unmet need is for highly specific criteria for clinical trials in early/de novo PD.

Brainstem network pathology and impaired respiratory drive as successive signatures in a rat model of Parkinson's disease.

Parkinson's disease (PD) is a devastating neurodegenerative disorder. Progressive destruction of midbrain dopaminergic neurons and axonal projections of the nigrostriatal pathway disrupts circuitry within the basal ganglia controlling movement. This article is protected by copyright. All rights reserved.

GBA-Associated Parkinson's Disease and Other Synucleinopathies.

GBA mutations are the most common known genetic cause of Parkinson's disease (PD). Its biological pathway may be important in idiopathic PD, since activity of the enzyme encoded by GBA, glucocerebrosidase, is reduced even among PD patients without GBA mutations. This article describes the structure and function of GBA, reviews recent literature on the clinical phenotype of GBA PD, and suggests future directions for research, counseling, and treatment.

Relationships between gait and emotion in Parkinson's disease: A narrative review.

Disturbance of gait is a key feature of Parkinson's disease (PD) and has a negative impact on quality of life. Deficits in cognition and sensorimotor processing impair the ability of people with PD to walk quickly, efficiently and safely. Recent evidence suggests that emotional disturbances may also affect gait in PD.

Clinical aspects of adherence to pharmacotherapy in Parkinson disease: A PRISMA-compliant systematic review.

Parkinson disease (PD) is the second most common neurodegenerative disease with various motor and nonmotor symptoms. Progressive course of PD requires frequent medication adjustments. Various combinations of drugs and dose regimens could be used to control symptoms. Thus, not surprisingly, adherence to pharmacotherapy is frequently suboptimal in these patients having negative effect on motor control and patient's quality of life.

A cross-brain regions study of ANK1 DNA methylation in different neurodegenerative diseases.

Recent epigenome-wide association studies in Alzheimer's disease have highlighted consistent robust neuropathology-associated DNA hypermethylation of the ankyrin 1 (ANK1) gene in the cortex. The extent to which altered ANK1 DNA methylation is also associated with other neurodegenerative diseases is not currently known. In the present study, we used bisulfite pyrosequencing to quantify DNA methylation across 8 CpG sites within a 118 bp region of the ANK1 gene across multiple brain regions in Alzheimer's dis...

Deep brain stimulation in Parkinson's disease.

Deep brain stimulation is an essential therapeutic tool in Parkinson's disease.

Quick Search